"Bortezomib" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A pyrazine and boronic acid derivative that functions as a reversible PROTEASOME INHIBITOR. It is used as an ANTINEOPLASTIC AGENT in the treatment of MULTIPLE MYELOMA and MANTLE CELL LYMPHOMA.
| Descriptor ID |
D000069286
|
| MeSH Number(s) |
D01.029.260.110.500 D01.132.285.500 D02.203.200.500 D03.383.679.450
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Bortezomib".
Below are MeSH descriptors whose meaning is more specific than "Bortezomib".
This graph shows the total number of publications written about "Bortezomib" by people in this website by year, and whether "Bortezomib" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 0 | 2 | 2 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 4 | 4 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 4 | 4 |
| 2010 | 0 | 4 | 4 |
| 2011 | 0 | 9 | 9 |
| 2012 | 0 | 6 | 6 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 3 | 3 |
| 2015 | 0 | 2 | 2 |
| 2016 | 1 | 2 | 3 |
| 2017 | 3 | 2 | 5 |
| 2018 | 2 | 0 | 2 |
| 2019 | 2 | 0 | 2 |
| 2020 | 3 | 3 | 6 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 5 | 5 |
| 2023 | 0 | 2 | 2 |
| 2024 | 2 | 2 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Bortezomib" by people in Profiles.
-
Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN. Blood Cancer J. 2024 07 08; 14(1):107.
-
Reduction of Filamin C Results in Altered Proteostasis, Cardiomyopathy, and Arrhythmias. J Am Heart Assoc. 2024 May 21; 13(10):e030467.
-
Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient-reported outcomes from GRIFFIN. Am J Hematol. 2024 07; 99(7):1257-1268.
-
Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study. Br J Haematol. 2024 Jun; 204(6):2227-2232.
-
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. Lancet Haematol. 2023 Oct; 10(10):e825-e837.
-
A plain language summary of daratumumab plus lenalidomide/bortezomib/dexamethasone in transplant-eligible Black patients with newly diagnosed multiple myeloma in the GRIFFIN study. Future Oncol. 2022 Dec; 18(40):4443-4456.
-
Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials. Transplant Cell Ther. 2023 03; 29(3):174.e1-174.e10.
-
Longitudinal Real-World Neuropathy and Patient-Reported Outcomes With Bortezomib and Lenalidomide in Newly Diagnosed Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2022 11; 22(11):e1000-e1008.
-
Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma. Oncologist. 2022 07 05; 27(7):e589-e596.
-
Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN. Blood Cancer J. 2022 04 13; 12(4):63.